Press Release|

Groundbreaking ceremony of SHL Group new site

Groundbreaking Image Resize 800x480

With the rapid growth of SHL Group and along with new innovations and technologies developed for pen and autoinjectors, the Taoyuan facility requires expansion of space and thus will be relocating to a new site in Nankan, Taoyuan. Construction started in Q4 of 2015.

In Q1 2018, all administrative offices and parts of the production will be relocated to the new site. The ground level has 12,349m2 area of space, to which a 7-stories high office-and manufacturing building with 62,603m2 total floor space is to be built on. The new facility will help SHL Group increase production capacity, improve efficiency, and raise overall manufacturing quality. This step will open new opportunities for implementing the latest manufacturing technologies.

To mark this special event, the official groundbreaking is set to be on the morning of February 2, 2016. President of SHL Group Roger Samuelsson will be present, along with the SHL Group’s senior executives such as Managing Director of Taiwan, Ulrich Faessler; Managing Director of US, Peter Noolandi; Executive VP of Commercial Operations & Business Development, Mats Persson; VP of Research & Development, Frank Isaksson; Executive VP of SHL Ventures, Stefan Ahlquist; VP of Quality Assurance & Regulatory Affairs, Shelley Chew, and VP of Supply Chain & Business Excellence, Richard Koch.

According to a recent industry report, the autoinjector market will reach US$2.5 billion globally in 2020. Autoinjectors have emerged as one of the fastest growing drug delivery solutions, driven by factors such as their ease of self-administration, allowance for at-home drug administration, decreased hospital visits (thereby reducing the cost of health care), and others. Commenting on this expansion, CEO and President of SHL Group, Roger Samuelsson states: “Customer needs have always been one of the top priorities of SHL Group. Every strategy that we make, we hope to exceed customer expectations. To meet the needs of a growing market for pen and autoinjectors, we must constantly invest in more advanced equipment and expand our production capacity.”

SHL Group keeps customer’s best interest at heart and with the expansion comes improved facility, products, and services.

Groundbreaking Ceremony information:

Date: 2 February 2016 (Tue)
Time: 10:30-14:00
Place: No. 44-1, Liufu Rd., Luzhu Dist., Taoyuan City 338, Taiwan (ROC)

About SHL

SHL Group is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit

Media contact:


Related News